ES2176236T3 - Derivado de indolin-2-ona. - Google Patents

Derivado de indolin-2-ona.

Info

Publication number
ES2176236T3
ES2176236T3 ES94907058T ES94907058T ES2176236T3 ES 2176236 T3 ES2176236 T3 ES 2176236T3 ES 94907058 T ES94907058 T ES 94907058T ES 94907058 T ES94907058 T ES 94907058T ES 2176236 T3 ES2176236 T3 ES 2176236T3
Authority
ES
Spain
Prior art keywords
sub
rent
lower rent
representative
arilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907058T
Other languages
English (en)
Spanish (es)
Inventor
Toru Chugai Esaki
Takashi Emura
Eiichi Hoshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2176236T3 publication Critical patent/ES2176236T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ES94907058T 1993-02-17 1994-02-17 Derivado de indolin-2-ona. Expired - Lifetime ES2176236T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6729793 1993-02-17
JP16726293 1993-05-31

Publications (1)

Publication Number Publication Date
ES2176236T3 true ES2176236T3 (es) 2002-12-01

Family

ID=26408486

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907058T Expired - Lifetime ES2176236T3 (es) 1993-02-17 1994-02-17 Derivado de indolin-2-ona.

Country Status (19)

Country Link
US (5) US5952511A (OSRAM)
EP (1) EP0685463B1 (OSRAM)
JP (1) JP3419539B2 (OSRAM)
KR (1) KR100226310B1 (OSRAM)
CN (1) CN1046268C (OSRAM)
AT (1) ATE217864T1 (OSRAM)
AU (1) AU6044894A (OSRAM)
CA (1) CA2156287C (OSRAM)
CZ (1) CZ290504B6 (OSRAM)
DE (1) DE69430664T2 (OSRAM)
ES (1) ES2176236T3 (OSRAM)
FI (1) FI112652B (OSRAM)
HU (1) HUT74105A (OSRAM)
MY (1) MY128102A (OSRAM)
NO (1) NO305201B1 (OSRAM)
PL (1) PL176710B1 (OSRAM)
RU (1) RU2128170C1 (OSRAM)
TW (1) TW281669B (OSRAM)
WO (1) WO1994019322A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
PT731091E (pt) * 1993-11-26 2002-05-31 Tanabe Seiyaku Co Derivados de 2-oxoindolina como antagonistas do receptor de colecistoquinina
WO1995024385A1 (en) * 1994-03-07 1995-09-14 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
AU2233097A (en) * 1996-03-11 1997-10-01 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of optically active indole compounds
WO1998002419A1 (en) * 1996-07-12 1998-01-22 Chugai Seiyaku Kabushiki Kaisha Cancer cell proliferation inhibitors
UA54403C2 (uk) * 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AP1717A (en) 1998-06-19 2007-01-30 Vertex Pharma Sulfonamide inhibitors of aspartyl protease.
JP2002531498A (ja) * 1998-12-04 2002-09-24 ニューロサーチ、アクティーゼルスカブ イオンチャネル活性剤としてのイサチン誘導体の使用方法
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ES2228451T3 (es) 1999-01-29 2005-04-16 Chugai Seiyaku Kabushiki Kaisha Promotores de condrogenesis y derivados de indolin-2-ona.
AU4483000A (en) * 1999-04-23 2000-11-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
AU2001236058A1 (en) * 2000-03-10 2001-09-17 Chugai Seiyaku Kabushiki Kaisha Preparations for chondrogenesis
US7612065B2 (en) 2000-04-21 2009-11-03 Vertex Pharmaceuticals Incorporated Inhibitors of c-JUN N-terminal kinases (JNK)
EP1363881A2 (en) * 2000-06-21 2003-11-26 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2001268607A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Company Piperidine amides as modulators of chemokine receptor activity
JP4897221B2 (ja) * 2002-12-20 2012-03-14 チバ ホールディング インコーポレーテッド アミン類の合成及びその合成のための中間体
CN1324009C (zh) * 2003-01-30 2007-07-04 普文英 化合物1-n-甲氧基-2-氧-吲哚-3-乙酰胺及其药物用途
ZA200703996B (en) * 2004-10-27 2008-09-25 Kissei Pharmaceutical Indoline compound and process for producing the same
WO2008027692A2 (en) * 2006-08-02 2008-03-06 Abu-Ageel Nayef M Led-based illumination system
US20090050905A1 (en) * 2007-08-20 2009-02-26 Abu-Ageel Nayef M Highly Efficient Light-Emitting Diode
US20100202129A1 (en) * 2009-01-21 2010-08-12 Abu-Ageel Nayef M Illumination system utilizing wavelength conversion materials and light recycling
US8987310B2 (en) 2009-10-30 2015-03-24 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
CN102516153B (zh) * 2011-12-14 2014-03-12 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
WO2015077572A1 (en) 2013-11-22 2015-05-28 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
KR102161674B1 (ko) * 2014-02-18 2020-10-05 주식회사 대웅제약 이사틴 유도체 및 이의 제조방법
CN113456631B (zh) * 2021-08-06 2022-06-21 徐州医科大学 一种靶向acsl1的小分子药物及其在治疗子宫内膜癌中的应用
CN117777002A (zh) * 2023-12-04 2024-03-29 华南理工大学 一种3,3-二取代氧化吲哚衍生物的不对称合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
JPS62228072A (ja) 1985-12-20 1987-10-06 Kissei Pharmaceut Co Ltd 3−アミノインドリン−2−オン誘導体
JPS62234080A (ja) 1985-12-20 1987-10-14 Kissei Pharmaceut Co Ltd インドリン−2−オン誘導体
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
JPS62270576A (ja) 1986-05-19 1987-11-24 Kissei Pharmaceut Co Ltd イサチン誘導体
JPS63156771A (ja) 1986-12-19 1988-06-29 Kissei Pharmaceut Co Ltd 3−アミノインドリン−2−オン誘導体
JPS62156771A (ja) * 1986-12-19 1987-07-11 Tokyo Shokai:Kk 処方箋処理装置
US4876259A (en) * 1987-01-05 1989-10-24 E. I. Du Pont De Nemours And Company 3,3-disubstituted indolines
EP0442878A4 (en) * 1988-04-05 1991-10-23 Abbott Laboratories Derivatives of tryptophan as cck antagonists
CA2088980C (en) * 1990-08-31 2002-04-16 David C. Horwell Pro-drugs for cck antagonists
WO1992007830A2 (en) * 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
CA2055094A1 (en) * 1990-11-13 1992-05-14 Mark G. Bock Cholecystokinin antagonist
JPH05104510A (ja) * 1991-10-18 1993-04-27 Inax Corp 基板へのモルタル塗布方法

Also Published As

Publication number Publication date
US6031111A (en) 2000-02-29
DE69430664T2 (de) 2003-01-30
NO953235L (no) 1995-10-09
JPH0748349A (ja) 1995-02-21
NO305201B1 (no) 1999-04-19
CZ290504B6 (cs) 2002-08-14
FI112652B (fi) 2003-12-31
ATE217864T1 (de) 2002-06-15
PL176710B1 (pl) 1999-07-30
FI953866A7 (fi) 1995-08-16
AU6044894A (en) 1994-09-14
WO1994019322A1 (en) 1994-09-01
HU9502415D0 (en) 1996-05-28
EP0685463B1 (en) 2002-05-22
EP0685463A4 (OSRAM) 1996-01-03
EP0685463A1 (en) 1995-12-06
KR100226310B1 (ko) 1999-10-15
KR960701011A (ko) 1996-02-24
US6127544A (en) 2000-10-03
RU2128170C1 (ru) 1999-03-27
CZ209695A3 (en) 1995-12-13
TW281669B (OSRAM) 1996-07-21
US5952511A (en) 1999-09-14
MY128102A (en) 2007-01-31
CN1117727A (zh) 1996-02-28
CA2156287A1 (en) 1994-09-01
DE69430664D1 (de) 2002-06-27
US6114536A (en) 2000-09-05
JP3419539B2 (ja) 2003-06-23
US6207836B1 (en) 2001-03-27
NO953235D0 (no) 1995-08-17
FI953866A0 (fi) 1995-08-16
CN1046268C (zh) 1999-11-10
PL310168A1 (en) 1995-11-27
HUT74105A (en) 1996-11-28
CA2156287C (en) 2005-12-27

Similar Documents

Publication Publication Date Title
ES2176236T3 (es) Derivado de indolin-2-ona.
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2079520T3 (es) Nuevos antiepilepticos.
ES2106855T3 (es) Analogos de 3-benciliden-1-carbamoil-2-pirrolidona.
ES2097872T3 (es) Fenilpirazolidinonas como agentes broncodilatadores y antiinflamatorios.
AU9057191A (en) N-substituted lactams useful as cholecystokinin antagonists
PA8610601A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
TW200716619A (en) Heterocyclic compound
DE69229674D1 (de) 5-ht4 rezeptor antagonisten
ES2153373T3 (es) Derivados de tienobenzodiazepina para el tratamiento de trastornos del sistema nervioso central.
ES2126097T3 (es) Derivados de diesteres fosfonicos.
CO5011105A1 (es) Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
NO943133L (no) Benzodiazepinderivater egnet til bruk som CCK-reseptorantagonister
DK0711283T3 (da) Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
NO970356L (no) PTH eller PTHrP antagonister
ES2181697T3 (es) 4-cianofeniliminoheterociclos.
EA200870346A1 (ru) Удлинители цепи
GT199900113A (es) Inhibidores de las fkbp.
DE59706174D1 (de) Melamin-polycarbonsäureamide und ihre Verwendung als Korrosionsschutzmittel
AR240859A2 (es) Composicion herbicida que contiene un derivado de difenil eter, dicho compuesto y procedimiento paraprepararlo
BRPI0412512A (pt) método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina
ES2176434T3 (es) Derivados de benzodiazepina, sales de los mismos, y farmacos que los contienen.
AR010200A1 (es) Derivados de aza-antraciclinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PA8473501A1 (es) 2- aminopiridinas que contienen sustituyentes de anillos condensados
ES2044971T3 (es) Procedimiento para la obtencion de derivados de indolopirazino-benzodiacepinas.